This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Orwoll, E. S. Articles by Cain, D. F. Search for Related Content PubMed PubMed Citation Articles by Orwoll, E. S. Articles by Cain, D. F. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Seniors' Health

Collagen N-Telopeptide Excretion in Men: The Effects of Age and Intrasubject Variability¹

Bone and Mineral Unit, Oregon Health Sciences University and Veterans Administration Medical Center (E.S.O.), Portland, Oregon 97201; Veterans Administration Medical Center and Medical University of South Carolina (N.H.B.), Charleston, South Carolina 29401; Veterans Administration Medical Center and Emory University (M.S.N.), Atlanta, Georgia 30033; and Ostex International, Inc. (K.A.F., M.B.P., N.J.S.M., D.F.C.), Seattle, Washington 98134

Address all correspondence and requests for reprints to: Eric S. Orwoll, M.D., Bone and Mineral Unit (CR113), Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon 97201.

Biochemical markers of bone resorption are useful for evaluating metabolic bone diseases. A three-center study was performed in 253 men, 21–86 yr of age, to determine the normal range of urinary N-telopeptide of type I collagen (NTX/creatinine) in a nonfasting, second void, morning specimen, to define the biological variability and to examine the relationship between NTX/creatinine and age. Men with disorders or taking medications known to alter bone turnover, or with a serum creatinine level greater than 2 mg/dL were excluded. Results are expressed as nanomoles of bone collagen equivalents (BCE) per mmol creatinine. In a subset of individuals over age 30 yr, additional second void morning urine specimens were obtained at 2, 3, and 4 days (short term study) and at 2, 3, and 4 months (long term study) after the first specimen. After collection, samples were shipped to one laboratory for analysis. Multiple samples from the same subject were analyzed in separate assays. It was found that urinary NTX/creatinine was significantly higher in 45 men, aged 21–30 yr, than in 206 men, aged 31–86 yr (48 ± 22 vs. 33 ± 15 nmol/L BCE/mmol/L creatinine; P < 0.00001). Values did not otherwise change with age. The range of values in men aged 21–30 yr was 4–92 nmol/L BCE/mmol/L creatinine. The range for men over age 30 yr was 3–63 nmol/L BCE/mmol/L creatinine, essentially the same as that previously reported for premenopausal women. The coefficient of variation was determined in each individual for the short term (n = 36) and long term studies (n = 35) and averaged 18% and 19%, respectively. There was no correlation between short term and long term coefficient of variations. In summary, urinary NTX/creatinine is higher in men aged 21–30 yr than in men over age 30 yr and may reflect continued skeletal maturation. Intrasubject variability of urinary NTX/creatinine in short term and long term studies has been defined for clinical purposes.

This article has been cited by other articles:

				P Szulc, A Montella, and P D Delmas High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study Ann Rheum Dis, September 1, 2008; 67(9): 1249 - 1255. [Abstract] [Full Text] [PDF]

				B. Z. Leder, A. B. Araujo, T. G. Travison, and J. B. McKinlay Racial and Ethnic Differences in Bone Turnover Markers in Men J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3453 - 3457. [Abstract] [Full Text] [PDF]

				F. Scopacasa, J.M. Wishart, A.G. Need, M. Horowitz, H.A. Morris, and B.E.C. Nordin Bone Density and Bone-Related Biochemical Variables in Normal Men: A Longitudinal Study J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2002; 57(6): M385 - 391. [Abstract] [Full Text]

				M. Kleerekoper Biochemical Markers of Bone Turnover: Why Theory, Research, and Clinical Practice Are Still in Conflict Clin. Chem., August 1, 2001; 47(8): 1347 - 1349. [Full Text] [PDF]

				M. J. Seibel, M. Lang, and W.-J. Geilenkeuser Interlaboratory Variation of Biochemical Markers of Bone Turnover Clin. Chem., August 1, 2001; 47(8): 1443 - 1450. [Abstract] [Full Text] [PDF]

				S. A. Stoch, R. A. Parker, L. Chen, G. Bubley, Y.-J. Ko, A. Vincelette, and S. L. Greenspan Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2787 - 2791. [Abstract] [Full Text] [PDF]

				F. Iqbal, J. Michaelson, L. Thaler, J. Rubin, J. Roman, and M. S. Nanes Declining Bone Mass in Men With Chronic Pulmonary Disease* : Contribution of Glucocorticoid Treatment, Body Mass Index, and Gonadal Function Chest, December 1, 1999; 116(6): 1616 - 1624. [Abstract] [Full Text] [PDF]

				M. Wichers, E. Schmidt, F. Bidlingmaier, and D. Klingmuller Diurnal Rhythm of CrossLaps in Human Serum Clin. Chem., October 1, 1999; 45(10): 1858 - 1860. [Full Text] [PDF]

				N. B. Watts Clinical Utility of Biochemical Markers of Bone Remodeling Clin. Chem., August 1, 1999; 45(8): 1359 - 1368. [Abstract] [Full Text] [PDF]